… The evolving treatment landscape for ATTR amyloidosis brings … However, TTR monomers
can undergo a major … abnormal amyloid fibril form (Citation3); TTR in its amyloid conformation …

… Center for Drug Evaluation and Research and the nonprofit Amyloidosis … Amyloidosis
Forum on advancing drug development in ATTR amyloidosis in an evolving treatment landscape. …

… Tests undertaken as part of the diagnostic process may therefore not be as useful in the
long-term monitoring of the changing state of ATTRv amyloidosis. Indeed, tests and …

… By contrast, ATTR CA is being increasingly recognized as a more common cause of heart
failure with preserved ejection fraction (HFpEF), with transthyretin amyloid deposits found at …

… treatment. We will additionally focus on recent advances in treatment for transthyretin
amyloidosis… including myocardial PET may also have an evolving role in CA. Hopefully in the future…

… pathogenic mutations reduce the stability of TTR tetramers as compared with the … TTR
amyloid fibrils in different sites, leading to progressive multisystem dysfunction. Citation1 Amyloid …

… The use of standard HF therapy in ATTR-CA will evolve with more experience and …
antibody that binds to misfolded TTR amyloid but not to native circulating TTR, thus clearing …

… cells or transthyretin (TTR) amyloidosis (ATTR), … transthyretin amyloid cardiomyopathy (ATTR-CM)
to the practicing cardiologist, this statement focuses on its diagnosis and management…

… are rapidly changing the natural history of ATTRv amyloidosis. Thus… treatment. As well, the
progressive nature of ATTRv raises the issue of presymptomatic testing and risk management …

… was determined they had localized amyloid deposits without systemic involvement; or if
follow-up data were unavailable. Patients undergoing all forms of treatment were included in this …